Alterity Therapeutics
ATHE
13 hedge funds and large institutions have $361K invested in Alterity Therapeutics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
494% more capital inflows, than outflows
Capital inflows: $49.8K | Capital outflows: $8.38K
18% more funds holding
Funds holding: 11 → 13 (+2)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$30K |
| 2 |
Morgan Stanley
New York
|
+$18.9K |
| 3 |
Advisor Group
Phoenix,
Arizona
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7.96K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$423 |
ATHE Hedge Fund Activity: Q2 2017 in Review
13 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2017, worth a combined $361K — down 18% from $442K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ATHE positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $30K. The largest seller was UBS Group, cutting an estimated $7.96K.
- 13 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2017, up from 11 in Q1 2017.
- Funds reported $361K of Alterity Therapeutics stock for Q2 2017, down 18% quarter-over-quarter.
- 2 funds opened new Alterity Therapeutics positions in Q2 2017 and 0 closed out, a net change of +2 holders.
- The largest Alterity Therapeutics buyer in Q2 2017 was Citadel Advisors, an estimated $30K added.
- The largest Alterity Therapeutics seller in Q2 2017 was UBS Group, an estimated $7.96K sold.
Based on aggregated 13F filings for Q2 2017.